Mark D Vincent
Overview
Explore the profile of Mark D Vincent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melosky B, Vincent M, McGuire A, Brade A, Chu Q, Cheema P, et al.
Int J Cancer
. 2024 Jun;
155(6):963-978.
PMID: 38900018
Cure of cancer is a sensitive and multidimensional concept that is challenging to define, difficult to assert at the individual patient level, and often surrounded by controversy. The notion of...
2.
Preti B, Sanatani M, Breadner D, Lakkunarajah S, Scott C, Esmonde-White C, et al.
Curr Oncol
. 2023 Aug;
30(8):7713-7721.
PMID: 37623040
The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly...
3.
Yu E, Allan A, Sanatani M, Lewis D, Warner A, Dar A, et al.
BMC Cancer
. 2022 Jul;
22(1):746.
PMID: 35804307
Background: Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods: We prospectively collected CTC...
4.
Malthaner R, Yu E, Sanatani M, Lewis D, Warner A, Dar A, et al.
Thorac Cancer
. 2022 May;
13(13):1898-1915.
PMID: 35611396
Background: We compared the health-related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I-III esophageal cancer. Methods: A total of 96 patients were randomized to standard...
5.
Yaremko B, Capaldi D, Sheikh K, Palma D, Warner A, Dar A, et al.
Int J Radiat Oncol Biol Phys
. 2022 May;
113(5):1072-1084.
PMID: 35550405
Purpose: To determine whether functional lung avoidance based on He magnetic resonance imaging (MRI) improves quality of life (QOL) for patients undergoing concurrent chemoradiotherapy (CCRT) for advanced non-small cell lung...
6.
Breadner D, Vincent M, Correa R, Black M, Warner A, Sanatani M, et al.
Lung Cancer
. 2022 Feb;
165:145-151.
PMID: 35124411
Introduction: Blood-based liquid biopsies examining circulating tumour DNA (ctDNA) have increasing applications in non-small cell lung cancer (NSCLC). Limitations in sensitivity remain a barrier to ctDNA replacing tissue-based testing. We...
7.
Preti B, Pencz A, Cowger J, Vincent M, Breadner D
Case Rep Oncol
. 2021 Oct;
14(2):1189-1193.
PMID: 34703435
This case discusses a 62-year-old woman with de novo metastatic lung adenocarcinoma (PD-L1 >50% with a KRAS G12C mutation, ALK and EGFR negative) who was on pembrolizumab for 1 year...
8.
Raphael J, Batra A, Boldt G, Shah P, Blanchette P, Rodrigues G, et al.
Clin Lung Cancer
. 2020 Jan;
21(2):106-113.e5.
PMID: 31992521
Randomized trials showed inconsistent survival benefit with immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer with low programmed death-ligand 1 (PD-L1) tumors (< 1%) and in elderly...
9.
Dranitsaris G, Zhu X, Adunlin G, Vincent M
Expert Rev Pharmacoecon Outcomes Res
. 2018 Apr;
18(4):351-357.
PMID: 29681201
After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity...
10.
Ferguson P, Vincent M, Koropatnick J
J Pharmacol Exp Ther
. 2017 Oct;
364(1):46-54.
PMID: 29061656
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors...